stockrowVericel Corporation
VCEL Healthcare Biotechnology
Vericel Corporation’s revenue for fiscal 2025 (year ended December 2025) was $276.3 million, up 16.5% from fiscal 2024.
- Revenue
- +26.5%
- EPS
- +180.0%
- Free cash flow
- −19.4%
Quarter to September 2026, against a year earlier
Follow VCEL
Alert me
Vericel Corporation (VCEL) Price to free cash flow
As of 5 November 2026, Vericel Corporation (VCEL) trades at a price to free cash flow of 45.4×. Over the past ten years it has ranged from 0.0× (September 2025) to 1,251× (April 2024); the current reading is higher than 62% of that period. That is above the Biotechnology industry median of 24.8× and above the Healthcare sector median of 21.1×.
Price to free cash flow, daily
Embed this chart
Annual newest first
| Period | Price to free cash flow | Change |
|---|---|---|
| FY2025 | 73.2× | — |
| FY2024 | 0.0× | — |
| FY2023 | 213× | 81.36% |
| FY2022 | 117× | 35.76% |
| FY2021 | 86.5× | (7.47%) |
| FY2020 | 93.4× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | Price to free cash flow | Change |
|---|---|---|
| Sep 2026 | 35.5× | (3.69%) |
| Jun 2026 | 36.9× | 7.13% |
| Mar 2026 | 34.4× | (53.04%) |
| Dec 2025 | 73.2× | (6.07%) |
| 43 more quarters | Free account |
Against its own ten years
Price to free cash flow against peers
| Company | Price to free cash flow |
|---|---|
| PVLA Palvella Therapeutics, Inc. compare | n/m |
| PHVS Pharvaris N.V. compare | n/m |
| BHVN Biohaven Ltd. compare | n/m |
| VERA Vera Therapeutics, Inc. compare | n/m |
| CLDX Celldex Therapeutics, Inc. compare | n/m |
| IMNM Immunome, Inc. compare | n/m |
| AUPH Aurinia Pharmaceuticals Inc compare | 12.2× |
| ADMA ADMA Biologics Inc compare | 24.5× |
| VCEL Vericel Corporation | 45.4× |
| Biotechnology industry median | 24.8× |
| Healthcare sector median | 21.1× |
| Market median | 14.1× |
What Price to free cash flow is
Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.
Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))
More on VCEL
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement